LABETALOL HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Labetalol Hydrochloride patents expire, and what generic alternatives are available?
Labetalol Hydrochloride is a drug marketed by Apothecon, Baxter Hlthcare Corp, Caplin, Gland Pharma Ltd, Hikma, Hospira, Rising, Steriscience, Appco, Cadila Pharms Ltd, Epic Pharma Llc, Eywa, Heritage Pharma, Innogenix, Par Form, Rubicon, Sandoz, Teva, Unichem, Watson Labs, and Zydus Pharms. and is included in twenty-six NDAs.
The generic ingredient in LABETALOL HYDROCHLORIDE is labetalol hydrochloride. There are fourteen drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the labetalol hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Labetalol Hydrochloride
A generic version of LABETALOL HYDROCHLORIDE was approved as labetalol hydrochloride by HERITAGE PHARMA on August 3rd, 1998.
Summary for LABETALOL HYDROCHLORIDE
| US Patents: | 0 |
| Applicants: | 21 |
| NDAs: | 26 |
| Finished Product Suppliers / Packagers: | 40 |
| Raw Ingredient (Bulk) Api Vendors: | 109 |
| Clinical Trials: | 67 |
| Patent Applications: | 824 |
| Formulation / Manufacturing: | see details |
| What excipients (inactive ingredients) are in LABETALOL HYDROCHLORIDE? | LABETALOL HYDROCHLORIDE excipients list |
| DailyMed Link: | LABETALOL HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for LABETALOL HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Loma Linda University | N/A |
| Zagazig University | Phase 2 |
| Nebraska Methodist Health System | Phase 4 |
Pharmacology for LABETALOL HYDROCHLORIDE
| Drug Class | beta-Adrenergic Blocker |
| Mechanism of Action | Adrenergic beta-Antagonists |
